-
1 week ago | 
buff.ly | Lin Zhiyin
(Yicai) June 19 -- Multiple primary market investors told Yicai they are closely watching for the resumption of initial public offerings by unprofitable biopharmaceutical startups on the Chinese mainland. Investors expect to hear more details after Wu Qing, chairman of the China Securities Regulatory Commission, announced yesterday that Shanghai’s Star Market will introduce a new "growth tier" aimed at supporting promising startups.
-
2 weeks ago | 
buff.ly | Lin Zhiyin
(Yicai) June 10 -- China National Biotec Group plans to acquire a controlling stake in Pacific Shuanglin Bio-Pharmacy, in a deal that could transform the competitive landscape of China’s blood products industry. Pacific Shuanglin’s controlling shareholder has signed a framework agreement with CNBG to transfer its entire 21.03 percent stake in the company, the Guangdong-based target said late yesterday.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) June 5 -- Shares of Wantai Biological Pharmacy surged by their daily trading limit after the Chinese firm's nine-valent human papillomavirus vaccine became the first such China-made jab to receive regulatory approval and also only the second worldwide. Wantai [SHA: 603392] surged 10 percent to CNY78.36 (USD10.92) a share as of 10.55 a.m. in Shanghai today, bringing its market capitalization to CNY99.1 billion (USD13.8 billion).
-
4 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 30 -- As Hong Kong and Shanghai’s biopharmaceutical ecosystems become increasingly intertwined, Shanghai is looking to leverage Hong Kong as a “super-connector” to help local drugmakers break into global markets, according to a Shanghai government official overseeing the development of the biomedical industry.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 23 -- Shares of Chinese drugmaker Hengrui Pharmaceutical soared nearly 30 percent on their first day of trading on the Hong Kong Stock Exchange. The stock [HKG: 1276] closed 25 percent up at HKD55.05 (USD7.03), giving the Jiangsu province-based firm a market capitalization of HKD365.5 billion (USD46.7 billion). Hengrui’s Shanghai-listed shares [SHA: 600276] fell 1.6 percent to CNY54.50 (USD7.57) today.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 21 -- The number of pharmacies in China dropped in the fourth quarter of last year, with drugstores struggling due to the rapid growth of healthcare e-commerce. Some 14,100 brick-and-mortar pharmacies closed in China in the three months ended Dec. 31, while only 10,700 opened, according to figures from health industry data and consulting service platform Zhongkang CMH. Their total number fell 0.5 percent from a quarter earlier.
-
1 month ago | 
yicaiglobal.com | Ma Xiaohua |Lin Zhiyin |Wu Simin
(Yicai) May 16 -- If the United States and China are forced to decouple in the pharmaceutical sector, this could push up US drugmakers’ costs by half, industry insiders said, in response to a recent statement by the US Treasury Secretary that although the US does not seek a full break from China, it does want to bring key industries like pharmaceuticals back to US soil.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 15 -- Hillhouse Group has sold HKD2.08 billion (USD266 million) worth of BeiGene’s Hong Kong-listed shares, capitalizing further on a substantial rally in the biopharmaceutical giant’s stock price this year. Soon after the sale, the Chinese private equity giant showed up as a cornerstone investor in drugmaker Hengrui Pharmaceuticals’ upcoming secondary listing in Hong Kong, Yicai learned.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 14 -- InnoCare Pharma posted a profit in the first quarter of this year for the first time, mainly thanks to a surge in sales of the Chinese firm's core leukemia drug. Net profit was CNY18 million (USD2.5 million) in the three months ended March 31, compared with a net loss of CNY142.4 million (USD19.7 million) a year earlier, according to the Beijing-based firm's financial report released late yesterday. Revenue surged 130 percent to CNY381.3 million (USD52.8 million).
-
1 month ago | 
yicaiglobal.com | Wu Ziye |Tong Xin |Chen Shanshan |Lin Zhiyin
We sent you a codeEnter it below to verify via You'll need a passwordMake sure it's 8 characters or moreSHOW PASSWORD/HIDE PASSWORDSuccess! Welcome to Yicai GlobalFind your Yicai Global accountCheck your emailWe've sent an email to with a confirmation code. Enter the code below to reset your password. If you don't see the email, check your junk, spam or other folders. Change your passwordStrong passwords include numbers,letters,and special characters.
